tbuckley/cabot-search huggingface dataset:
Abstract #5551: The impact of expression of BER proteins on therapeutic effect of combining temozolomide with methoxyamine in melanoma cells
Authors: Yanling Miao, Alina Bulgar, Ralph Tuthill, Ernest Borden, Stanton Gerson, Lili Liu
Journal: Cancer Research (2009)

Base excision repair (BER) is a highly coordinated cellular biochemical system essential to cell survival. Variability of expression of BER proteins may affect the dynamics of the repair pathway or change the repair rate that determines the cellular sensitivity to the cytotoxicity exerted by alkylating agents. In the present study, we examined the relationship between the expression of BER proteins and therapeutic effect of temozolomide (TMZ) and the combination of TMZ and methoxyamine (MX), a BER inhibitor, in melanoma cells in vitro and in xenografts. The levels of BER proteins (including MPG, UDG, APE, and Pol \#946;) were measured by western blotting assay in 4 cell lines, SkmCI-1, WM164, A375, and WM9. Results revealed that BER proteins were coordinately and differentially expressed in these melanoma cell lines, higher in A375 and much lower in WM164 cells. There were no significant differences in MGMT and MLH1-MSH2, two well known TMZ resistant factors in these two cell lines. To determine the role of BER proteins in TMZ cytotoxicity, clonogenic survival studies were performed in A375 and WM164 cells. The sensitivity to TMZ alone in these two cell lines was assessed by IC90 value produced by survival assay, showing 490 µM in A375 and 570 µM in WM164 cells. When cells were treated with the combination of TMZ and MX, MX efficiently potentiated TMZ cytotoxicity by 3 folds in A375 but failed to enhance the killing effect of TMZ in WM164 cells. Similar results were observed in xenografts. In xenograft study, MX enhanced TMZ antitumor effect, resulting in tumor growth delays of 13 days in mice receiving the combination of TMZ (80 mg/kg) and MX (2 mg/kg) i.p daily for five days in comparison to 6 days in mice treated with TMZ alone. No enhancement of TMZ-antitumor activity by MX was observed in mice carrying WM164 melanoma xenografts. The results suggest that the failure of TMZ-potentiation by MX in WM164 cells was related to the low activity of BER proteins, particularly low levels of MPG DNA glycosylase.  Deficiency of the BER proteins would decrease the formation of AP sites, the targets for MX action. These results indicate that BER proteins may be differentially expressed in tumor cells, which particularly impact the therapeutic effect of combining TMZ with MX.   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5551.
HEMOPTYSIS IN TUBERCULOSIS, WITH A DIFFERENTIAL DISCUSSION OF OTHER CAUSES
Authors: Lewis J. Moorman
Journal: Annals of Internal Medicine (1944)

Article1 September 1944HEMOPTYSIS IN TUBERCULOSIS, WITH A DIFFERENTIAL DISCUSSION OF OTHER CAUSESLEWIS J. MOORMAN, M.D., F.A.C.P.LEWIS J. MOORMAN, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-21-3-447 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIf romancing were permissible in medicine, we might indulge in an interesting consideration of the sharp turns hemoptysis has wrought in the lives of important personages and in the history of the world. It often precipitates a psychological panic through the fear of impending dissolution and, then, spurns death in order to condition destiny. Allen K. Krause once said, "Sometimes a man will write a new kind of history. Its keynote will be the shaping of human destiny by disease." In such a history, hemoptysis should have a prominent place.Hippocrates' statement that "the spitting of pus follows the spitting...Bibliography1. JACKSONDIAMOND CLS: Haemorrhage from the trachea, bronchi and lungs of nontuberculous origin, Am. Rev. Tuberc., 1942, xlvi, 126. Google Scholar2. WARE J: Haemoptysis as a symptom, Publications of The Massachusetts Medical Society, 1860. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Oklahoma City, Oklahoma*Presented before a Regional Meeting of the American College of Physicians, Kansas City, Missouri, May 8, 1943. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byXXVII Hemoptysis 1 September 1944Volume 21, Issue 3Page: 447-454KeywordsFearHistory of medicine ePublished: 1 December 2008 Issue Published: 1 September 1944 PDF downloadLoading ...
Elevated Levels of the Wnt Antagonist DKK1 and RANKL in the Bone Marrow Environment Link Chronic Heart Failure With Osteoporosis
Authors: David M. Leistner
Journal: Circulation (2009)

Abstract #2369 David M. Leistner, Florian H. Seeger, Birgit Assmus, Jörg Honold, Ulrich Fischer-Rasokat, Thomas Trepels, Mahir Karakas, Univ Hosp of Frankfurt, Frankfurt am Main, Germany; Tino Röxe, Stefanie Dimmeler, Ctr of Molecular Med, Goethe Univ Frankfurt, Frankfurt am Main, Germany; Andreas M. Zeiher, Univ Hosp of Frankfurt, Frankfurt am Main, Germany David M. Leistner, 2009 Finalist and Presenting Author
New Drug Formulations Offer Hope for Easing Global Burden of Malaria
Authors: Rebecca Voelker
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins
Authors: Giorgio Stassi, Diana Di Liberto, Matilde Todaro, Ann Zeuner, Lucia Ricci-Vitiani, Antonella Stoppacciaro, Luigi Ruco, Felicia Farina, Giovanni Zummo, Ruggero De Maria
Journal: Nature Immunology (2000)
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
Authors: Jonathan I. Epstein, Michael J. Zelefsky, Daniel D. Sjoberg, Joel B. Nelson, Lars Egevad, Cristina Magi-Galluzzi, Andrew J. Vickers, Anil V. Parwani, Victor E. Reuter, Samson W. Fine, James A. Eastham, Peter Wiklund, Misop Han, Chandana A. Reddy, Jay P. Ciezki, Tommy Nyberg, Eric A. Klein
Journal: European Urology (2015)
Sensitive Glass Microfibre‐Based Histamine Analysis for Allergy Testing in Washed Blood Cells
Authors: P. Stahl Skov, H. Mosbech, S. Norn, B. Weeke
Journal: Allergy (1985)

The new microfibre method for allergy testing is based on basophil histamine release after challenge with suspected allergens in samples of 50 μl washed blood cells. Released histamine is bound to microfibres and measured after removal of interfering substances by washing. The microfibre method was compared with the conventional leukocyte histamine release assay in 18 allergic patients tested with 10 different allergens. It was found that the same individuals responded with histamine release to the same allergens in both assays, and the number of responders was almost identical. Also the dose‐response curves and the cell sensitivity were almost identical, which further substantiated identity between the results obtained by the new microfibre method and the conventional assay. A comparison between the microfibre method and in vivo provocation tests showed good agreement when comparing the number of positive and negative responses in these test. The new method overcomes the problems in allergy testing, where only small amounts of blood are available and many tests have to be carried out.
Abstract #LB-260: Changes in circulating tumor cells over time correlates with D-dimer and serum prostate-specific antigen levels in patients with refractory prostate cancer.
Authors: Joseph Khoury, Dorothy Adcock, Stefan Tiefenbacher, James Symanowski, Oscar Goodman, Yupo Ma, David Ward, James Tung, Beth Grobaski, Nicholas Vogelzang, Louis Fink
Journal: Cancer Research (2009)

Background: Elevated D-dimer levels in patients with prostate cancer are associated with tumor burden as measured by serum levels of prostate-specific antigen (PSA), but their association with circulating tumor cell (CTC) numbers has not been evaluated. In this study, we assess the relationship between D-dimer, CTC, and PSA and ask whether changes in these parameters are concordant when measured over a period of time during therapy for refractory prostate cancer. Methods: Concomitant quantitative determinations of serum D-dimer levels, CTC, and PSA were serially obtained on 24 patients with refractory prostate cancer during the course of therapy. CTC levels were measures in 7.5 mL of whole blood. Classification analysis was performed by classifying patients according to increasing (positive velocity) or decreasing (negative velocity) D-dimer, CTC, or PSA levels over time using analysis of variance (ANOVA). Results: Patients had a median age of 63.4 years (range, 53 to 78 years). PSA values ranged from 0.2 to 9,051.4 ng/mL, D-dimer levels ranged from 125 to 15,608 ng/mL, and CTC numbers ranged from 0 to 4732 cells/7.5 cc whole blood. A significant correlation was identified between CTC velocity and each of PSA (r=0.71) and D-dimer (r=0.48) velocity (p   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-260.
Major adverse cardiac events after the Ross operation in 1606 patients: current status of the German-Dutch Ross registry with up to 19 years follow-up
Authors: Derek Robinson, M Bechtel, J Boehm, C Botha, E Charitos, K Ferrari-Kuehne, A Gorski, T Hanke, R Hetzer, M Huebler, J Hoerer, M Misfeld, A Moritz, H Sievers, U Stierle, J Takkenberg, G Ziemer
Journal: Circulation (2009)

Background: The Ross operation has reached the 5th decade with good long term results from the pioneer series. There is gaining concern however about autograft and allograft durability over time. Furthermore, reports about major adverse cardiac events (MACE) as required by the latest guidelines update, in a large Ross patient cohort are scarce in the literature. It was the aim of this study to report the MACE in patients being treated with the Ross procedure.

Methods: 1606 patients (mean age 39.3±16.1, range 0.0 –70.5y), male=1202, female=404) underwent a Ross procedure with a mean follow-up of 5.4±3.9y (7817 pt years, range 0.1–18.7y). Data from the prospective German-Dutch Ross Registry with 12 participating centers were evaluated in accordance to the 2008 guidelines of reporting mortality and morbidity after cardiac valve interventions.

Results: Follow-up was complete in 94.6%. All cause mortality was n=69 (4.3%, cardiac=40, 2.5%, unknown=1). Overall survival was 97.7% at 5y and 95.2% at 10y. Structural and non-structural autograft failure with the need of reoperation occurred in n=70 (4.4%), autograft endocarditis with reoperation was present in n=12 (0.8%) resulting in a freedom from autograft reoperation of 97,1% at 5y and 93.0 % at 10y (mean time to reoperation 6.1±4.72y, median 5.7y). Allograft failure with the need of reoperation occurred in n=56 (3.5%) with a freedom from allograft reoperation of 96.9% at 5y and 93.7% at 10y (mean time to reoperation 4,3±3.8y, median 2,6y). 10 valvuloplasties were included in these numbers. Freedom from autograft and allograft reoperation was 94.5% at 5y and 88.1% at 10y. Infective endocarditis (conservative or medically treated) occurred in n=45 (linearized occurrence rate 0.57%/patient-year), thrombotic and thromboembolic events (including transient ischemic attacks) were observed in n=38 (linearized occurrence rate 0.48%/patient-year).

Conclusion: A low rate of MACE in the long term after the Ross operation was observed in the registry. The large cohort enables to define subsets of patients who could be at risk for autograft reoperation. Caution ought to be attended to allograft and autograft endocarditis, since almost one fifth of all reoperations were associated with infective endocarditis.
Strain Differences in Growth of Mouse Mammary Tumors&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Francesco Squartini
Journal: JNCI Journal of the National Cancer Institute (1961)

Four hundred female mice of strains C3H, BALB/cf, and RIII, all susceptible to the development of mammary tumors, bearing the milk agent, and endowed with physiologic hormonal stimulations (normal breeding), have been studied. The analysis concerns the rate of fertility, tumor incidence, tumor age, survival of tumor-bearing mice, occurrence of multiple tumors, growth rate of tumors, frequency of partial regressions, and type of tumor growth. Under the same conditions, C3H and BALB/cf mice possess a nearly parallel behavior, but in RIII mice the behavior of tumors is quite different. The tumors occurring in the two former strains possess a high growth rate, rarely undergo partial regressions, and grow in regular types, mostly a sigmoidal curve. In contrast, tumors occurring in the RIII strain possess a low growth rate, frequently undergo partial regressions, and develop irregular and unpredictable types of growth. Possible causes for these differences are suggested.
Role of Tc-99m sestamibi scintigraphy in the diagnosis and surgical decision-making process in primary hyperparathyroid disease.
Authors: MASSIMO CASTELLANI, EUGENIO RESCHINI, VIRGILIO LONGARI, ALESSANDRA PARACCHI, SABRINA CORBETTA, GIORGIO MAROTTA, PAOLO GERUNDINI
Journal: Clinical Nuclear Medicine (2001)

Purpose Ultrasound (US) and scintigraphy are used most frequently of all the available imaging techniques for the preoperative evaluation of patients with possible primary hyperparathyroid disease. The aim of this study was to assess the value of dual-phase Tc-99m MIBI scintigraphy compared with US in the detection of adenomatous or hyperplastic glands and in the surgical decision-making process for patients with a biochemical diagnosis of primary hyperparathyroid disease. Methods Ninety-seven patients with increased levels of parathyroid hormone and calcium, and at least 6 months' follow-up after US and scintigraphy, were examined retrospectively to assess the influence of the diagnostic work-up on the therapeutic decision of the referring clinicians and to evaluate the sensitivity of these diagnostic tools in the surgically treated patients. Forty-eight patients underwent surgery. Results Parathyroid adenomas were found in 43 patients and hyperplasia in 1, whereas 4 patients had no evidence at surgery. The sensitivity and specificity rates were 84.4% and 95.9% for scintigraphy, and 66.6% and 98.6% for US, respectively. Of the 49 nonsurgically treated patients, 35 had negative results with both MIBI and US; only 3 had positive findings with both imaging methods. Patients treated conservatively had significantly lower parathyroid hormone and serum calcium levels than did the patients who had surgery. Conclusions The data suggest that the high sensitivity of dual-phase MIBI scintigraphy can improve the detection of hyperfunctioning parathyroid glands. Furthermore, despite the controversy surrounding the use of imaging methods in the preoperative assessment of primary hyperparathyroid disease, these data suggest that the decision of the clinician to order surgery for a patient with a moderate increase of serum PTH level may be influenced by the results of the imaging methods.
Abstract 486: Allogeneic Mesenchymal Stem Cells in Cellular Cardiomyoplasty: Mechanisms of Cardiac Repair
Authors: Konstantinos E Hatzistergos, Henry Quevedo, Behzad N Oskouei, Qinghua Hu, Ramesh Mazhari, Juan P Zambrano, David Valdes, Gary S Feigenbaum, Jose R Rodriguez, Irene S Margitich, Jeffrey M Zimmet, Concepción Revilla, Alan W Heldman, Ian McNiece, Joshua M Hare
Journal: Circulation (2008)

Background- Although there is significant enthusiasm for cell-based therapies, whether administered cells differentiate into cardiomyocytes (CM) or exert their effects solely by paracrine signaling remains controversial. We hypothesized that allogeneic bone marrow-derived mesenchymal stem cells (aMSCs) regenerate the infarcted heart by cell autonomous mechanisms involving differentiation into myocytes, endothelial cells, vascular smooth muscle cells and the stimulation of endogenous precursor cell proliferation. Methods and Results - Seventeen female swine underwent myocardial infarction. Three days later, they received intramyocardial injections of male GFP pos aMSCs (n=7), placebo (n=7) or no injection (n=3). Animals were euthanized at 24h (n=1 aMSCs, n=1 placebo), 72h (n=3 aMSCs, n=3 placebo) and 2 weeks (n=3 aMSCs, n=3 placebo, n=3 controls) after injections. Within 24h, engrafted aMSCs exhibited lineage commitment into CM (GATA4, α-sarcomeric actinin) but not vascular precursors. By 72h, CM differentiation rates increased substantially (GFP pos /GATA pos : 23.4±3.2% of GFP pos cells at 72h vs 13.4±5.4% at 24h) as well as vascular lineage committment (GFP pos /KDR/Factor VIII pos : 1.3±0.4%). Importantly, aMSCs migrated throughout ischemic but not viable myocardium. Two weeks later, MSCs had differentiated into mature vessels and CM. Cardiac regeneration was accompanied by recruitment of endogenous c-kit pos cells at infarct (IZ) and border (BZ) zones of the treated animals, compared both to placebo and control (p≤0.001). In contrast to the untreated animals, c-kit cells were localized in clusters in the IZ and BZ of the treated hearts and formed connexin-43 and N-cadherin connections with each other and the GFP pos aMSCs, resembling stem cell niches. The number of the c-kit pos /GATA-4 pos cells within the niches was significantly higher at the BZ of the treated hearts (3.9±1.6%) compared to placebo and control (p≤0.05), indicative of an endogenous repair mechanism. Conclusions- Together these findings offer important mechanistic insight into the basis of aMSCs ability to achieve post-MI cardiac regeneration, and illustrate that the cells exert both cell dependent and host dependent effects.
All in the family of medicine
Authors: Syed M Ahmed
Journal: BMJ (2001)

Mr A to Mr B: “I am puzzled. You always make nice comments about Mr C. On the other hand, Mr C always says bad things about you. Why?”

Mr B to Mr A: “Perhaps because we are both liars.”

Recently, a close friend told me that another friend, a gastroenterologist, had told him that I “wasted my talent” by becoming a family doctor, who was “a gatekeeper and nothing else.” My feelings were hurt, but I was not surprised. When I chose family medicine, …
Abstract 11314: Statin and Aspirin Use in a High Risk CHD HMO Population Modeled to Prevent 4,930 Ascvd Events and Save the Health Care System up to $123 Million in 3 Years
Authors: Robert J Dudl, Roshan Shah, Wiley Chan, Ronald D Scott
Journal: Circulation (2014)

We assessed the use of statin and aspirin treatment in patients with CHD risk &gt;10% vs. patients with CHD risk &gt;20% and the potential reduction in ASCVD events and health care costs. We utilized ARCHeS and the Archimedes Model, a large bio-mathematical model built with randomized controlled trial data for predicting responses to therapies, for the simulations and analyses. In measuring financial effects, we used Medicare data to predict processes and costs of care for the events. Patients selected were from Kaiser Permanente (KP) aged 20-79 years old who had a calculated Framingham CHD risk score of ≥10% or ≥20% and were not on a statin according to the KP drug database. We assumed 80% adherence &amp; 80% eligibility after other exclusions such as cancer, frailty, and refusing therapy. RESULTS: This resulted in 19,610 members with CHD risk &gt;20% and 156,986 with CHD risk &gt;10% that would be offered the treatment. Compared to standard of care, ASCVD events were reduced by 5.88%, 20.1%, and 33.2% in the &gt;20% risk group and by 3.14%, 12.5%, and 24.88% in the &gt;10% risk group at 3, 10, and 20 years, respectively. This resulted in prevention of adverse events for patients which in turn drove medical care system savings per person of $1,638, $6,453, and $9,288 for the &gt;20% risk group, and $999, $4,871 and $9,672 for &gt;10% risk group, respectively. Population extrapolations are shown below. CONCLUSIONS: These data suggest the treatment would improve patient outcomes by reducing ASCVD events and decrease medical care system resource use within 3 years by treating members at 20% CHD risk levels. However, significantly more event savings would occur if the 10% CHD risk group were included and continued in both groups for at least 20 years.
Advising the Tuberculous About Employment.
Authors: Elliott Jh
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal